Investors Relations

Shaping the future of medical cannabis

Stay informed about Balancial’s growth, market strategy, and investment opportunities as we expand across Europe.

Balancial is entering the Danish market.

Vision

We envision a European market in which medicinal cannabis is available as a safe and a preferred treatment method, changing millions of lives for the better. Every day.

People

Our team of industry experts work passionately to unfold the potential of medicinal cannabis.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lars Erik Råen
Lars Erik Råen
Lars Erik Råen
CEO, Balancial Group. Board Member Balancial Denmark and Germany

Background from banking and finance, business development, and as an investor. Has in recent years been involved in development, and financing for several start-ups in Norway and internationally. Co-founder of Balancial and has held position as CEO and part of the board in Balancial and its subsidiaries since 2020. Background: BSc, Economics & Administration, specializing in finance.

Daniel Petter Lunde
Daniel Petter Lunde
Daniel Petter Lunde
CFO and Board Member, Balancial Group

Daniel has long and broad experience from the financial sector where he held different positions within corporate finance. Since 2017 mr Lunde has served as managing partner at Westpoint Partners, an investment and BD consultancy firm which is the majority shareholder in Balancial. Co-founder of Balancial where he became CFO in 2021. BSc, Economics & Administration, specializing in business development.

Matthias Filkorn
Matthias Filkorn
Matthias Filkorn
Managing Director, Balancial Germany

Matthias have 15 years experience from managing sales and business development in the German pharmaceutical industry. He comes from the position as Head of Business Unit Services at market leader Cansativa GmbH. In addition to being a certified Paramedic, Matthias holds a Masters degree in Health Economics from the Universities of Cologne and Bremen.

Christine Abraham
Christine Abraham
Christine Abraham
COO / Head of QM, Balancial Germany

Christine was General Manager at Medizinalcannabis Vertriebs GmbH in Austria, where she played a key role in establishing their Quality Management System and obtaining certifications. With expertise in quality management, cannabinoids, and regulatory affairs, she brings valuable knowledge to her role as COO at Balancial GmbH. She holds university degrees in Chemistry, French, and Pedagogy.

Bo Tandrup
Bo Tandrup
Bo Tandrup
CEO, Balancial Denmark

Bo has a background in product development and project management in the pharma industry. He is behind several successful start-ups in the pharmaceutical industry and has been hired as an advisor to, among others, Goldman Sachs and McKinsey in processes related to acquisitions in the pharmaceutical industry. Bo holds a Master’s degree in Pharmaceutical Sciences from the Royal Danish School of Pharmacy.

Ørnulf Samdal
Ørnulf Samdal
Ørnulf Samdal
Chairman of the Board, Balancial Group

Ørnulf daily lawyer with his own practice in Bergen. He has extensive experience from several listed companies in roles such as CEO and legal director. He also has experience in international business management and several board positions.

Trine Teigland
Trine Teigland
Trine Teigland
Board member, Balancial Group

Trine has a broad business background from shipping, marketing, and sales, as well as strategy development and market analysis. Portfolio manager and investor through Teigland Eiendom AS and holds board positions in listed Lifecare.

Dr. Bjarte Askeland
Dr. Bjarte Askeland
Dr. Bjarte Askeland
Board member, Balancial Group

Bjarte Askeland is a section chief physician in Orthopedic Anesthesia at Haukeland Hospital, and general manager of the Norwegian Anesthesiology Association. Askeland has a master's degree from the Faculty of Medicine, University of Bergen 1979-1985, and has worked as a specialist in anaesthesiology since 1996.

Leif Bo Ølgaard
Leif Bo Ølgaard
Leif Bo Ølgaard
Board member and Advisor, Balancial Denmark

Leif has over 30 years of experience in the pharmaceutical and petrochemical industries. He has extensive expertise in consultancy, business development, line management, and project management. Leif has played a key role in designing process equipment, automating production facilities, and implementing project management models at Novo Nordisk A/S.

Nina Askgaard
Nina Askgaard
Nina Askgaard
Competent Person, Balancial Denmark

Nina holds the regulatory title «Competent Person» and is responsible for Balancial's QMS system. Nina has extensive experience in the pharmaceutical industry, including from Novo Nordisk in Denmark and later as a consultant and consultant. Education: MSc Pharmaceutical Sciences.

Maik Dobiey
Maik Dobiey
Maik Dobiey
Sales Director, Germany

Maik brings deep experience in the German medical cannabis market, with an extensive network across pharmaceutical companies, wholesalers, and specialized pharmacies. Most recently, he served as head of pharmacy sales and delivered strong growth. Maik is fluent in German, English, and Spanish, and has international experience from working in over 16 countries. He brings a strategic mindset and hands-on approach to Balancial’s product-sourcing strategy and sales efforts in both Germany and Denmark.”

Marius Hjermitslev Larsen
Marius Hjermitslev Larsen
Marius Hjermitslev Larsen
Management Assistant, Balancial Denmark

Marius er ansvarlig for forberedelse af betalinger i bankens system, vedligeholdelse af vores hjemmeside, samt håndtering af vores sociale medieplatforme, herunder LinkedIn, Twitter og Facebook. Derudover koordinerer han samarbejdet med vores reklamebureau og støtter vedligeholdelsen af faciliteterne. Marius udfører også ad hoc-opgaver for at sikre, at vores daglige drift forløber gnidningsfrit.

Carla Ferrao
Carla Ferrao
Carla Ferrao
GMP Technician, Balancial Denmark

Carla Ferrao first joined Balancial as GMP Technician but quickly advanced and assumed responsibility for Regulatory Affairs. Prior to joining Balancial Carla worked at the National Food Institute at the Technical University of Denmark. Carla holds a Master’s degree in Chemical Engineering from the University of Southern Denmark.

Investor news

Read all

Key information

Balancial is a leading distributor of medical cannabis, committed to providing high-quality, safe, and effective products across Europe. Our business model focuses on regulatory compliance, strategic partnerships, and market expansion.

April 2021
Danish Import & Distribution License Granted
The company is granted a license for the import and distribution of medical cannabis in Denmark.
June 2023
German License Acquired via Acquisition
The company obtains a license in Germany through the acquisition of a licensed company.
April 2024
First Product Approved in Denmark
Our first product is approved under the Danish pilot program.
September 2024
Supply Agreement with GroVida
Agreement signed with Portuguese company GroVida for the supply of cannabis to Germany.

Market information

The medical cannabis market in Europe is evolving rapidly, with increasing demand and regulatory support.

Partners

Balancial collaborates with industry-leading cannabis producers, research institutions, and healthcare providers.

Key partnerships

Helius (New Zealand) – Market leader in GMP-certified medicinal cannabis.
GroVida (Portugal) – European leader in cultivation, supplying Balancial’s German market.
Pharmacy Networks – Partnerships to distribute Balancial’s prescription-based cannabis products.

Register interest

Fill out the form below, and we are happy to come back to you with relevant information

We will contact you shortly, usually within 24 hours on business days. If you have urgent matters, please call us on the numbers above in the contact list.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Disclaimer

The information on this page is provided for informational purposes only and does not constitute an offer or solicitation to invest in Balancial. Any investment in the company involves risks, including regulatory uncertainties and market conditions.

Read full disclaimer
->